Amneal Pharmaceuticals, Inc.
NASDAQ:AMRXDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $7.62B
- Beta
- 1.32
- P/E (TTM)
- 43.4
- EPS (TTM)
- $0.37
Volume 1.91M
Average 1.75M
AMRX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Amneal Pharmaceuticals, Inc.NASDAQ: AMRX
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow turns positive
Q2 FY2026 financing cash flow was $77.38M, compared with -$41.69M a year earlier. Trailing-twelve-month financing cash flow was $69.63M. Over 3 fiscal years it compounded at -33.4% a year.
Context
- Financing cash flow amounted to 1.0% of revenue in FY2025, down 6.5 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $77.38M or moves back toward the trailing-twelve-month quarterly average of $17.41M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (31.53M) USD
- Year-over-year change
- +85.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31.53M) | +85.1% |
| FY2024 | 2024-12-31 | (211.79M) | +0.4% |
| FY2023 | 2023-12-31 | (212.57M) | -99.4% |
| FY2022 | 2022-12-31 | (106.62M) | +22.8% |
| FY2021 | 2021-12-31 | (138.12M) | — |
Financing Cash Flow vs competitors
How AMRX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +129.7% is the 2nd highest of 11, against a peer median of -43.5%.
- Financing cash flow amounts to 2.2% of revenue for AMRX, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹3.08B INR | +123.1% | — | 0.9% | |
| LTM Jun 2026 | $1.91B USD | -50.8% | -30.6% | 13.0% | |
| LTM Jun 2026 | $1.1B USD | -1097.9% | +16.1% | 10.1% | |
| LTM Jun 2026 | $578.8M USD | -6.1% | — | 14.0% | |
| LTM Jun 2026 | $401M USD | -83.4% | +13.1% | 2.3% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $174M USD | +278.3% | -33.3% | 13.1% |
| LTM Mar 2026 | $147.6M USD | -36.1% | — | 21.8% | |
| LTM Mar 2026 | $83.13M USD | +1.5% | +36.6% | 11.5% | |
| LTM Jun 2026 | $69.63M USD | +129.7% | -33.4% | 2.2% | |
| LTM Mar 2026 | $21.65M USD | -107.9% | +24.7% | 2.3% | |
| LTM Mar 2026 | $1.98M USD | -74.4% | +48.5% | 4.7% | |
| Peer median (excluding AMRX) | — | -43.5% | +16.1% | 10.8% | |
Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 10.62M | (254.79M) | (48.72M) | (73.88M) | 72.06M |
| Depreciation & Amortization | 233.41M | 240.18M | 229.4M | 236.19M | 223.57M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 31.85M | 26.82M | 27.77M | 31.95M |
| Change in Working Capital | (133.59M) | (59.95M) | (47.19M) | (4.07M) | (204.52M) |
| Accounts Receivables | (16.31M) | (79.07M) | 125.8M | (162.16M) | (120.57M) |
| Inventory | (49.02M) | (102.4M) | (126.18M) | (130.53M) | (87.03M) |
| Accounts Payables | (43.93M) | 109.57M | (94.45M) | 235.14M | 21.32M |
| Other Working Capital | (24.34M) | 11.95M | 47.64M | 53.48M | (18.23M) |
| Other Non-Cash Items | 131.38M | 107.81M | 185.26M | 109.08M | 216.93M |
| Operating Cash Flow | 241.82M | 65.1M | 345.58M | 295.1M | 339.99M |
| Capital Expenditures | (47.73M) | (90.6M) | (69.19M) | (74.99M) | (70.06M) |
| Acquisitions (Net) | (141.54M) | (84.71M) | 0 | 11.99M | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.21M) | (40.8M) | (22.39M) | (14.65M) | (42.2M) |
| Investing Cash Flow | (194.18M) | (174.31M) | (69.19M) | (63M) | (112.26M) |
| Debt Repayment | (79.18M) | (38.27M) | 22.65M | (185.12M) | 26.27M |
| Common Stock Issued | 853K | 0 | 0 | 0 | 1.96M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (59.8M) | (68.35M) | (235.23M) | (26.67M) | (59.76M) |
| Financing Cash Flow | (138.12M) | (106.62M) | (212.57M) | (211.79M) | (31.53M) |
| Effect of Forex Changes | 102K | (5.68M) | 65K | (999K) | (1.68M) |
| Net Change in Cash | (90.38M) | (221.51M) | 63.88M | 19.31M | 194.52M |
| Free Cash Flow | 194.09M | (25.5M) | 276.39M | 220.11M | 269.93M |
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
Intrinsic Alpha fair value
Locked
Current Price
$21.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.